The FDA has approved a third respiratory syncytial virus vaccine for high-risk adults aged younger than 50 years — a ...

They aren't just "pandemic stocks." ...

WASHINGTON, Feb 23 (Reuters) - U.S. Food and Drug Administration Commissioner Marty Makary on Monday defended his agency's position and record on mRNA vaccines, days after it changed course and agreed ...

Total revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 ...

The global nasal drug delivery technology market is projected to grow at a CAGR of approximately 7% over the next five years.

The approval represents a win in what’s been a difficult regulatory environment of late for vaccine makers, and could boost ...

First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total ...

In a report released yesterday, Kerry Holford from Berenberg Bank maintained a Hold rating on Pfizer, with a price target of $25.00. The company’s shares closed yesterday at $27.30. Holford covers the ...

Dublin, March 10, 2026 (GLOBE NEWSWIRE) -- The "Comirnaty (Tozinameran) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus ...

(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...